US89422G1076
© BusinessWire
11.12.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 20,300 shares of its common stock. These inducement RSUs are subject to...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,700 shares of its common stock. These inducement RSUs are subject to...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were significantly more likely to reach proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET
Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
TD Cowen Immunology &...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Third Quarter 2025 Financial Results
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update.
“We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Report Third Quarter 2025 Financial Results
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
The webcast and dia...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
News Preview
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9.
In focal segmental glomerulosclerosis (FSGS), the Company will present:
A late-breaking analysis from the DU...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 228,600 shares of its common stock to 43 new employees, consisting of inducement stock options to purchase an aggregate of 50,000 shares of common stock a...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
TVTX
LISTED
NASDAQ
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
News Preview
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidel...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 69,300 shares of its common stock. These inducement RSUs are subject to t...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee is no longer needed. The sNDA remains under...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism, taking place September 2-6 in Kyoto, Japan.
New long-term data from Cohort 6 of the Phase 1/2 COMPOSE open-label extension (OLE) Study demonstrat...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.08.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for the treatment of IgA nephropathy (IgAN). The update reduces the frequency o...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Report Second Quarter 2025 Financial Results
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
The webcast and dia...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the t...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the te...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025.
The Company will present new data evaluating biomarkers of disease progression in IgA nephr...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure.
This press release features multim...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present seven abstracts at the upcoming European Renal Association (ERA) Congress in Vienna, Austria, June 4-7.
Presentations will include new data on the use of FILSPARI in IgA nephropathy (IgAN) from the Phase 2 SPARTACUS Study which demonstrated that FILSPARI pro...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target a...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the te...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
BofA Securities 2025 Healthcare Conference
Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT
Jefferies Global Healthcare Conference
Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET
Scotiab...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports First Quarter 2025 Financial Results
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.
“As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this lead...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
News Preview
Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Report First Quarter 2025 Financial Results
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
The webcast and dial-in i...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA.
The late-breaking oral presentation will feature new analyses from the Phas...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
News Preview
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to pur...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.02.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
News Preview
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present at Upcoming Investor Conferences
News Preview
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its commo...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
News Preview
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 mill...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Third Quarter 2024 Financial Results
News Preview
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
News Preview
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics to Report Third Quarter 2024 Financial Results
News Preview
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
News Preview
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego....
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2024
TVTX
LISTED
NASDAQ
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its com...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
News Preview
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
News Preview
Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
News Preview
Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
TVTX
LISTED
NASDAQ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
